Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02079974 |
Recruitment Status :
Withdrawn
First Posted : March 6, 2014
Last Update Posted : August 28, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Endometriosis | Drug: Pravastatin | Not Applicable |
- Initial grading of pain by a Linear Analogue Scale (LAS) from 1-10
- Initial blood biochemistry including liver function test, lipid profile, creatine/BUN, creatine kinase
- 3 months of treatment with statins (Pravastatin) in a dose of 40mg daily
- Supplementation with CoQ10 (200mg) daily for 3 months
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis |
Study Start Date : | July 2014 |
Actual Primary Completion Date : | July 2014 |
Actual Study Completion Date : | July 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Pravastatin
Pravastatin sodium 20mg PO daily
|
Drug: Pravastatin
20 mg pravastatin sodium daily for 3 months
Other Name: pravastatin sodium |
- subjective assessment of pain [ Time Frame: 3 months ]Linear analogue scale for each component of pain (dysmenorrhea; pelvic pain; dyspareunia)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 38 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- female patients of reproductive age group (18-38 years) with a clinical or surgical diagnosis of endometriosis with pain symptoms
Exclusion Criteria:
- use of hormonal suppression for pain control (OCP, GnRHa) within 6-months
- history of surgery for endometriosis within 6- months
- current renal or hepatic active disease
- current or history of myopathic disease
- medication that may interact with statins (erythromycin, gemfibrosil, antifungals, antiretrovirals, other cholesterol lowering drugs)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02079974
Canada, Ontario | |
Mount Sinai Hospital, University of Toronto | |
Toronto, Ontario, Canada, M5G 1X5 |
Principal Investigator: | Robert Casper, MD | Dept of Obstetrics and Gynecology, University of Toronto |
Responsible Party: | Dr. Robert F. Casper, Professor, Dept of Obstetrics and Gynecology, Toronto Centre for Advanced Reproductive Technology |
ClinicalTrials.gov Identifier: | NCT02079974 |
Obsolete Identifiers: | NCT02084667 |
Other Study ID Numbers: |
4169720110 |
First Posted: | March 6, 2014 Key Record Dates |
Last Update Posted: | August 28, 2020 |
Last Verified: | August 2020 |
endometriosis pain fertility |
Endometriosis Pravastatin Anticholesteremic Agents Hypolipidemic Agents Antimetabolites |
Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |